CNM-Au8: An experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).

Expert opinion on investigational drugs（2023）

引用 1|浏览1

暂无评分

摘要

Oral treatment with CNM-Au8 failed to meet primary clinical and electrodiagnostic endpoints in phase 2/3 clinical trials. Despite this failure, a number of exploratory endpoints included in phase 2/3 trials suggest CNM-Au8 has the potential to significantly slow clinical worsening, improve quality of life, and prolong survival in ALS. Further study of CNM-Au8 in a phase 3 clinical trial is currently underway.

查看译文

关键词

Amyotrophic lateral sclerosis, ALS, motor neuron disease, CNM-Au8, MND, investigational drug

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要